Business Context and Reporting Period
This Form 8-K was filed by Abbott Laboratories on April 18, 2017. The report details the operational integration following the completion of the acquisition of St. Jude Medical, Inc. on January 4, 2017. Beginning with the first quarter of 2017, Abbott's Cardiovascular and Neuromodulation (ACN) business now includes its historical Vascular Products segment combined with the businesses of St. Jude Medical.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Instead, it announces a change in financial reporting methodology. On January 25, 2017, Abbott issued comparable historic revenue data for the ACN business for each quarter of 2016 and the full year, categorized into six specific product lines. The specific revenue figures are contained in Exhibit 99.1, which is referenced but not included in the text of this filing.
Material Changes
The primary material change is the restructuring of the ACN business reporting categories to reflect the St. Jude Medical acquisition. Abbott will now report ACN sales results in the following six categories:
- Rhythm Management: Traditional pacemakers, implantable cardioverter-defibrillators (ICDs), and bi-ventricular cardiac resynchronization therapy devices.
- Electrophysiology: Atrial fibrillation products.
- Heart Failure: Ventricular assist devices and the CardioMEMs HF system.
- Vascular: Coronary, endovascular, and vessel closure devices, diagnostic coronary imaging, and percutaneous heart pumps.
- Structural Heart: Heart valve replacement and repair devices, patent foramen ovale closure devices, and left atrial appendage closure products.
- Neuromodulation: Spinal cord stimulation, dorsal root ganglion stimulation, and deep brain stimulation products.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future performance, or specific risk factors beyond the standard legal disclaimer. The document states that the information contained in this Current Report and its Exhibit shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 to obtain the specific comparable revenue figures for the ACN business for 2016 by product category.
- Verify the integration timeline and financial impact of the St. Jude Medical acquisition in subsequent quarterly earnings reports.
- Confirm how the new six-category reporting structure aligns with historical segment reporting for trend analysis.